| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 9, 2025
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for...
Sep 19, 2025The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire
-
Feb 24, 2025
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025...
-
Sep 25, 2024
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several...
Apr 26, 2024Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN, April 26, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
Jan 8, 2024Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. DUBLIN, Jan. 8, 2024...
Aug 25, 2023Inceptiv automatically and instantly adjusts therapy based on signals from the spinal cord DUBLIN, Aug. 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology,...
Oct 26, 2022New Medtronic Neurovascular Co-Lab™ Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients...
-
Jul 14, 2022
Powered by a database of over 10,000 surgical cases, Medtronic continues to evolve the UNiD™ platform to help surgeons plan procedures, personalize care for their patients and predict...
-
May 13, 2022
Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif., May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...
-
Mar 24, 2022
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:...
Mar 23, 2022Medtronic and Harris Poll survey finds 4 in 5 report chronic back or leg pain is worse or unimproved since the COVID-19 pandemic began DUBLIN, March 23, 2022 /PRNewswire/ -- A new survey...
Feb 28, 2022Single-use device treats Eustachian tube dysfunction during office proceduresMedtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug...
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Jan 24, 2022Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and...
Jan 14, 2022DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN, Jan. 14, 2022 /PRNewswire/ -- Medtronic plc...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
-
Dec 13, 2021Study shows 57.1% of patients discontinued or reduced oral opioid prescription refills post-procedure and exhibited a decrease in payer costs¹
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases...
-
Sep 30, 2021Industry Leading Portfolio of Integrated Solutions Sets a New Standard for Minimally Invasive Spine Procedures, Beginning with MIS+ TLIF
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine...
-
Sep 28, 2021- Portfolio Features First Catheter Specifically Designed to Allow Neurointerventionalists Radial Artery Access, Delivers Advantages to Patients Treated for Stroke, Brain Aneurysms, Other Neurovascular Conditions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial...
-
Sep 22, 2021Medtronic Will Move to Request Litigation Proceedings Resume
Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed an additional...
-
Sep 22, 2021
As First Patient Is Enrolled in the Clinical Trial of Braive™ Growth Modulation System, Study Reaffirms Medtronic's Commitment to Pediatric Spine Innovation DUBLIN, Sept. 22, 2021 /PRNewswire/...
-
Sep 13, 2021Medtronic Receives Affirmation of Three Additional Sacral Neuromodulation Patents
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral...
-
Aug 6, 2021Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat...
Jun 10, 2021Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain ReliefMedtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free...
Jun 7, 2021The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient ComfortMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead...
-
Jun 3, 2021Compatibility of UNiD™ Rods with Medtronic's Spinal Systems Enables the Integration of AI-Driven Surgical Planning, Patient-Specific Spinal Implants and Robotic Assisted Surgery to Improve Procedural Efficiency, Precision and Outcomes
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of patient-specific UNiD™ Rods for use with Medtronic CD...
May 5, 2021New App Developed in Partnership with Higgs Boson Health, a Physician-Led Digital Health and Patient Engagement Solutions ProviderMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their...
-
Apr 27, 2021New Investigational Device Aims to Expand Access to Therapy for Patients with Incontinence; Underscores Medtronic's Leadership as Only Company to Offer Neuromodulation Options for Incontinence
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption...
-
Apr 26, 2021SyncAR™ Technology Uniquely Integrates with StealthStation™ S8 Surgical Navigation System and Expands the Use of Augmented Reality Into Operating Rooms to Enhance Precision and Efficiency
Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's SyncAR™ augmented reality (AR) technology...
-
Apr 21, 2021
First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health DUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...
-
Mar 22, 2021
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN, March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in...
Mar 17, 2021Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of Chronic Intractable Back PainMedtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™...
-
Feb 18, 2021
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of...
-
Feb 16, 2021
Dr. Gregory Poulter of OrthoIndy, Dr. Sharad Rajpal of Boulder Neurosurgical & Spine Associates and Dr. Eiman Shafa of Twin Cities Spine Center Are First in the U.S. to Complete Surgeries Using...
-
Feb 1, 2021
Acquisition of RIST Neurovascular Enhances Medtronic's Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions DUBLIN, Feb. 1, 2021 /PRNewswire/ -- Medtronic...
-
Jan 14, 2021
ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Medtronic...
Dec 15, 2020The OPuS One Clinical Study is the largest study with the most meaningful clinical results supporting the OsteoCool™ Technology to-dateMedtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study (as...
-
Nov 16, 2020
Acquisition Expands Medtronic's Artificial Intelligence and Data Capabilities, Becoming the First Company to Offer an Integrated Spine Solution Including AI-Driven Surgical Planning, Personalized...
-
Oct 29, 2020New Technologies Address Most Common Challenges During Head and Neck Surgery
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the NIM Vital™ nerve monitoring...
Oct 20, 2020Study Reports 84% Back Pain Responder Rate and 69% Profound Responder Rate at 12 Months(1)Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that...
Oct 7, 2020A World's First That Combines Innovative Technologies: Titan nanoLOCK™ Surface Technology and NavigationMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of Adaptix™ Interbody System, the first navigated titanium implant with Titan nanoLOCK™...
-
Oct 6, 2020ELITE is the Only Study of a Rechargeable Sacral Neurostimulation System to Include All Four Indications, Including Fecal Incontinence, Which Affects Millions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a...
-
Sep 25, 2020U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent
Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal...
-
Aug 20, 2020ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention
DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global,...
-
Aug 5, 2020First Patient Receives New Sacral Neuromodulation Device Implant at Cleveland Clinic
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for...
-
Aug 3, 2020World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans
DUBLIN, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug...
-
Jul 15, 2020Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery
DUBLIN and LYON, France, July 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea;...
-
Jun 25, 2020Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals
DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the...
-
Feb 25, 2020
DUBLIN, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 40th Annual Cowen and Company Healthcare...